Table 3.
Univariate and multivariate analyses for the risk factors of immune-related adverse events (irAEs).
| Variable | Category | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|---|
| OR | 95% CI | p-Value | OR | 95% CI | p-Value | ||
| Gender | Male | 1.151 | 0.444–2.985 | 0.772 | |||
| Age (years) | ≥65 years | 1.292 | 0.606–2.752 | 0.507 | |||
| Histology | Non-adenocarcinoma | 1.630 | 0.762–3.487 | 0.208 | |||
| ECOG PS score | 2 | 0.350 | 0.114–1.074 | 0.066 | 0.355 | 0.109–1.163 | 0.087 |
| Smoking status | Former/current | 0.656 | 0.305–1.410 | 0.280 | |||
| Treatment line | ≥Second | 0.593 | 0.271–1.299 | 0.192 | |||
| Driver gene alterlation | EGFR/ALK/ROS1 positive | 0.253 | 0.050–1.280 | 0.097 | 0.308 | 0.055–1.709 | 0.178 |
| Combination treatment | Yes | 0.833 | 0.389–1.784 | 0.639 | |||
| PD-L1 states test | ≥50% | 1.362 | 0.539–3.440 | 0.513 | |||
| CD4+ T lymphocytes | ≥266 M/L | 1.392 | 0.655–2.957 | 0.390 | |||
| CD8+ T lymphocytes | ≥288 M/L | 2.975 | 1.365–6.484 | 0.006 | 2.953 | 1.324–6.587 | 0.008 |
| Regulatory T lymphocytes | ≥17 M/L | 0.773 | 0.364–1.640 | 0.502 | |||
ECOG PS, Eastern Cooperative Oncology Group performance status; PD-L1, programmed cell death ligand 1; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; ROS1, V-ros UR2 sarcoma virus oncogene homolog 1.